Cargando…

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes

Detalles Bibliográficos
Autor principal:	Mahajan, Rajiv
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875741/ https://www.ncbi.nlm.nih.gov/pubmed/20523873 http://dx.doi.org/10.4103/0253-7613.56070

Ejemplares similares

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
por: Keche, Yogendra
Publicado: (2010)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata
por: Ali, Eman, et al.
Publicado: (2022)

Recently FDA-approved drug: A new hope for vitiligo patients?
por: Siddiq, Mohammad Arham, et al.
Publicado: (2022)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
por: Niafar, Mitra, et al.
Publicado: (2016)

FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
por: Sheikh, Ayesha, et al.
Publicado: (2022)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails
por: ul- Abideen, Zain, et al.
Publicado: (2021)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via, Michael A, et al.
Publicado: (2010)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

Determination of Doxazosin Mesylate in Tablets by RP-HPLC
por: Dhanya, B., et al.
Publicado: (2011)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
por: Kiseleva, Olga I., et al.
Publicado: (2015)

Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies
por: Badran, Mohamed M., et al.
Publicado: (2023)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Determination of Alkyl Methanesulfonates in Doxazosin Mesylate by Gas Chromatography-mass Spectrometer
por: Sitaram, C., et al.
Publicado: (2011)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Blood test to help diagnose type 1 diabetes approved by Food and Drug Administration
por: Mahajan, Rajiv
Publicado: (2015)

Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form
por: Anumolu, P. D., et al.
Publicado: (2016)

Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients
por: Nagata, Eiichiro, et al.
Publicado: (2016)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Development and Validation of a UV Spectrophotometric Method for the Simultaneous Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and Formulations
por: Anandakumar, K., et al.
Publicado: (2011)

Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients
por: Nagata, Eiichiro, et al.
Publicado: (2016)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
por: Spiegel, Lauren L., et al.
Publicado: (2020)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

A new kind of diabetes medication approved by the FDA: is there hope for obesity?
por: Dhirani, Danisha, et al.
Publicado: (2023)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o86erjj7fl4hlrlm3nsngjiqdn